Aficamten for Obstructive Hypertrophic Cardiomyopathy | NEJM

Whether the reversible cardiac myosin inhibitor aficamten can improve peak oxygen uptake in patients with symptomatic obstructive hypertrophic cardiomyopathy is unknown.
Research findings are summarized in a new Quick Take video.
To see the full article, follow this link: nej.md/3wmDzyl
#cardiology #clinicaltrials #nejm

[@Zehh35]

Incredible results! Congratulations to all involved in this research.

[@marcoimmunotherapy3737]

Thank you.

[@bostondan77]

Love this but sad the price of the drug will be $$$